309 related articles for article (PubMed ID: 16181544)
21. Frequent silencing of fragile histidine triad gene (FHIT) in Burkitt's lymphoma is associated with aberrant hypermethylation.
Hussain A; Gutiérrez MI; Timson G; Siraj AK; Deambrogi C; Al-Rasheed M; Gaidano G; Magrath I; Bhatia K
Genes Chromosomes Cancer; 2004 Dec; 41(4):321-9. PubMed ID: 15384174
[TBL] [Abstract][Full Text] [Related]
22. [Loss of heterozygosity of tumor suppressor genes at chromosome 3p in transitional cell carcinoma of urinary bladder].
Xiao Z; Zhang J; Zheng S; Li C; He Z; Cheng S; Gao Y
Zhonghua Yi Xue Za Zhi; 2002 Oct; 82(20):1375-7. PubMed ID: 12509916
[TBL] [Abstract][Full Text] [Related]
23. Loss of heterozygosity on chromosome 13q12-q14, BRCA-2 mutations and lack of BRCA-2 promoter hypermethylation in sporadic epithelial ovarian tumors.
Gras E; Cortes J; Diez O; Alonso C; Matias-Guiu X; Baiget M; Prat J
Cancer; 2001 Aug; 92(4):787-95. PubMed ID: 11550149
[TBL] [Abstract][Full Text] [Related]
24. Epigenetic silencing contributes to frequent loss of the fragile histidine triad tumour suppressor in basal cell carcinomas.
Goldberg M; Rummelt C; Laerm A; Helmbold P; Holbach LM; Ballhausen WG
Br J Dermatol; 2006 Dec; 155(6):1154-8. PubMed ID: 17107382
[TBL] [Abstract][Full Text] [Related]
25. Analysis of FHIT allelic imbalance/loss of heterozygosity and FHIT expression in cutaneous squamous cell carcinomas.
Gray SE; Kay E; Leader M; Mabruk M
J Cutan Pathol; 2008 Sep; 35(9):816-25. PubMed ID: 18494825
[TBL] [Abstract][Full Text] [Related]
26. Methylation of the 5' CpG island of the FHIT gene is closely associated with transcriptional inactivation in esophageal squamous cell carcinomas.
Tanaka H; Shimada Y; Harada H; Shinoda M; Hatooka S; Imamura M; Ishizaki K
Cancer Res; 1998 Aug; 58(15):3429-34. PubMed ID: 9699676
[TBL] [Abstract][Full Text] [Related]
27. Imprinted tumor suppressor genes ARHI and PEG3 are the most frequently down-regulated in human ovarian cancers by loss of heterozygosity and promoter methylation.
Feng W; Marquez RT; Lu Z; Liu J; Lu KH; Issa JP; Fishman DM; Yu Y; Bast RC
Cancer; 2008 Apr; 112(7):1489-502. PubMed ID: 18286529
[TBL] [Abstract][Full Text] [Related]
28. Detailed genetic and physical mapping of tumor suppressor loci on chromosome 3p in ovarian cancer.
Fullwood P; Marchini S; Rader JS; Martinez A; Macartney D; Broggini M; Morelli C; Barbanti-Brodano G; Maher ER; Latif F
Cancer Res; 1999 Sep; 59(18):4662-7. PubMed ID: 10493522
[TBL] [Abstract][Full Text] [Related]
29. Analysis of the fragile histidine triad gene in primary gastric carcinomas and gastric carcinoma cell lines.
Tamura G; Sakata K; Nishizuka S; Maesawa C; Suzuki Y; Iwaya T; Terashima M; Saito K; Satodate R
Genes Chromosomes Cancer; 1997 Sep; 20(1):98-102. PubMed ID: 9290961
[TBL] [Abstract][Full Text] [Related]
30. FHIT gene in gastric cancer: association with tumour progression and prognosis.
Noguchi T; Müller W; Wirtz HC; Willers R; Gabbert HE
J Pathol; 1999 Aug; 188(4):378-81. PubMed ID: 10440747
[TBL] [Abstract][Full Text] [Related]
31. Deletions of BRCA1/2 and p53 R248W gain-of-function mutation suggest impaired homologous recombination repair in fragile histidine triad-negative sebaceous gland carcinomas.
Becker K; Goldberg M; Helmbold P; Holbach LM; Loeffler KU; Ballhausen WG
Br J Dermatol; 2008 Dec; 159(6):1282-9. PubMed ID: 18717684
[TBL] [Abstract][Full Text] [Related]
32. Loss of heterozygosity at 3p14.2 in clear cell renal cell carcinoma is an early event and is highly localized to the FHIT gene locus.
Velickovic M; Delahunt B; Grebe SK
Cancer Res; 1999 Mar; 59(6):1323-6. PubMed ID: 10096566
[TBL] [Abstract][Full Text] [Related]
33. Fragile histidine triad gene inactivation in lung cancer: the European Early Lung Cancer project.
Verri C; Roz L; Conte D; Liloglou T; Livio A; Vesin A; Fabbri A; Andriani F; Brambilla C; Tavecchio L; Calarco G; Calabrò E; Mancini A; Tosi D; Bossi P; Field JK; Brambilla E; Sozzi G;
Am J Respir Crit Care Med; 2009 Mar; 179(5):396-401. PubMed ID: 19096006
[TBL] [Abstract][Full Text] [Related]
34. Reduced Fhit expression in sporadic and BRCA2-linked breast carcinomas.
Ingvarsson S; Agnarsson BA; Sigbjornsdottir BI; Kononen J; Kallioniemi OP; Barkardottir RB; Kovatich AJ; Schwarting R; Hauck WW; Huebner K; McCue PA
Cancer Res; 1999 Jun; 59(11):2682-9. PubMed ID: 10363992
[TBL] [Abstract][Full Text] [Related]
35. FHIT expression and hypermethylation in esophageal squamous cell carcinoma.
Noguchi T; Takeno S; Kimura Y; Uchida Y; Daa T; Yokoyama S; Gabbert HE; Mueller W
Int J Mol Med; 2003 Apr; 11(4):441-7. PubMed ID: 12632095
[TBL] [Abstract][Full Text] [Related]
36. The Fragile Histidine Triad gene and breast cancer.
Yang Q; Yoshimura G; Sakurai T; Kakudo K
Med Sci Monit; 2002 Jul; 8(7):RA140-4. PubMed ID: 12118213
[TBL] [Abstract][Full Text] [Related]
37. Homozygous deletion but not mutation of exons 5 and 8 of the fragile histidine triad (FHIT) gene is associated with features of differentiated thyroid carcinoma.
Yin DT; Wang L; Sun J; Yin F; Yan Q; Shen RL; Gao JX; He G
Ann Clin Lab Sci; 2010; 40(3):267-72. PubMed ID: 20689140
[TBL] [Abstract][Full Text] [Related]
38. Methylation status of fragile histidine triad (FHIT) gene and its clinical impact on prognosis of patients with myelodysplastic syndrome.
Lin J; Yao DM; Qian J; Wang YL; Han LX; Jiang YW; Fei X; Cen JN; Chen ZX
Leuk Res; 2008 Oct; 32(10):1541-5. PubMed ID: 18367246
[TBL] [Abstract][Full Text] [Related]
39. Clinicopathological significance of aberrant methylation of RARbeta2 at 3p24, RASSF1A at 3p21.3, and FHIT at 3p14.2 in patients with non-small cell lung cancer.
Tomizawa Y; Iijima H; Nomoto T; Iwasaki Y; Otani Y; Tsuchiya S; Saito R; Dobashi K; Nakajima T; Mori M
Lung Cancer; 2004 Dec; 46(3):305-12. PubMed ID: 15541815
[TBL] [Abstract][Full Text] [Related]
40. [Correlation between methylation of 5'-CpG islands and inactivation of FHIT gene in cervical cancer].
Shi HR; Wu QH; Suo ZH; Nesland JM
Ai Zheng; 2005 Jan; 24(1):7-11. PubMed ID: 15642192
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
